Fig. 1 · Structure

Documents & Downloads

Liquiritigenin

Cat. No. A12083 CAS 578-86-9
Liquiritigenin is a plant-derived highly selective estrogen receptor ?? agonist

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 100 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 18440233]
B16 IC50 5 μg/mL Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay [PMID: 15787450]
B16-BL6 IC50 97.7 μM Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay [PMID: 18440233]
CCRF-CEM IC50 > 25 μg/mL Cytotoxicity against human CEM cells after 72 hrs by MTT assay [PMID: 15787450]
DU-145 IC50 > 100 μM Cytotoxicity against human DU145 cells after 72 hrs by MTT assay [PMID: 20494492]
HCT-116 IC50 37.2 μM Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay [PMID: 20494492]
HCT-8 IC50 19.5 μg/mL Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay [PMID: 15787450]
HeLa IC50 > 100 μM Cytotoxicity against human HeLa cells after 72 hrs by MTT assay [PMID: 18440233]
HeLa IC50 > 100 μM Cytotoxicity against human HeLa cells after 72 hrs by MTT assay [PMID: 20494492]
HL-60 IC50 22.5 μg/mL Cytotoxicity against human HL60 cells after 72 hrs by MTT assay [PMID: 15787450]
HT-1080 IC50 > 100 μM Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay [PMID: 18440233]
K562 IC50 > 100 μM Cytotoxicity against human K562 cells after 72 hrs by MTT assay [PMID: 20494492]
Lewis lung carcinoma cell line IC50 > 100 μM Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay [PMID: 18440233]
MCF7 IC50 > 25 μg/mL Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay [PMID: 15787450]
MDCK CC50 301 μM Cytotoxicity against MDCK cells after 72 hrs [PMID: 24313801]
Peritoneal macrophage IC50 85 μM Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method [PMID: 27955927]
SGC-7901 IC50 92.4 μM Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay [PMID: 20494492]

17 records · Scroll to view more

Liquiritigenin Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Liquiritigenin from 3 published references. In vitro models include C2C12 cells.

Liquiritigenin In Vitro Studies

Liquiritigenin was evaluated in C2C12 cells through supplementation of growth media at 0.25 ng/mL. Cell proliferation significantly increased (5%) compared with non-treated cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell Proliferation in C2C12 Cells

Cell-based study · C2C12 cells [1]

C2C12 cells received growth media supplemented with Liquiritigenin at 0.25 ng/mL. Cell proliferation significantly increased (5%) compared with non-treated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell proliferationCell proliferation 5%[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.25 ng/mL
Exposure duration
one day
Method
growth media supplemented with liquiritigenin
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Liquiritigenin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.5. G. uralensis-EtOAc Derived Compounds Increased Myoblast Proliferation and Differentiation (S40, S41); 4. Materials and Methods > 4.6. Cell Proliferation Assay (S117); Figure 5 legend (S181, S185, S187)

Cell proliferation: Cell proliferation; comparator: Non-treated cells — 2. Results > 2.5. G. uralensis-EtOAc Derived Compounds Increased Myoblast Proliferation and Differentiation (S41); Figure 5 legend (S185)

Liquiritigenin In Vivo Studies

In female mice with bleomycin-induced pulmonary fibrosis, oral Liquiritigenin dose-dependently reduced mortality compared with the pulmonary fibrosis model group. Liquiritigenin also significantly reduced alveolar wall thickening and extracellular matrix deposition compared with the pulmonary fibrosis model group, with the most pronounced effect at 100 mg/kg. In male BALB/c mice with CP-induced AKI, intraperitoneal Liquiritigenin significantly reduced serum creatinine and urea nitrogen levels compared with the model group. [2,3]

Mortality in Bleomycin-Induced Pulmonary Fibrosis

Animal study · Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice [2]

Female mice with bleomycin-induced pulmonary fibrosis received oral Liquiritigenin at 25 mg/kg, 50 mg/kg, or 100 mg/kg. Liquiritigenin dose-dependently reduced mortality compared with the pulmonary fibrosis model group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The survival curve of mice was recorded.Reported result liquiritigenin dose-dependently reduced the mortality rate in bleomycin-induced pulmonary fibrosis mice[2]

Conditions shared by the study groups

Route
oral
Treatment course
on days 15–28
Vehicle
0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kgpulmonary fibrosis model group (intratracheal bleomycin on day 0 + oral 0.9% saline on days 15–28)liquiritigenin dose-dependently reduced the mortality rate in bleomycin-induced pulmonary fibrosis mice[2]
Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg
Model: Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice
Methods and source locations

Compound reported in the paper: Liquiritigenin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Experimental animals (S1, S3, S4, S5); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S81); Fig. 1 legend (S131)

The survival curve of mice was recorded.: The survival curve of mice was recorded.; comparator: pulmonary fibrosis model group (intratracheal bleomycin on day 0 + oral 0.9% saline on days 15–28) — Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S81); Fig. 1 legend (S131)

Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg · Materials and methods > Experimental animals (S5); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S81)

Serum Creatinine and Urea Nitrogen in CP-Induced AKI

Animal study · Male BALB/c mice; CP-induced AKI mice model; n = 9 mice/group [3]

Male BALB/c mice with CP-induced AKI received Liquiritigenin by intraperitoneal injection at 15 mg/kg body weight/day. Liquiritigenin significantly reduced serum creatinine and urea nitrogen levels compared with the model group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum creatinine levelsReported result liquiritigenin significantly reduced serum creatinine and urea nitrogen levels compared to the model group[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
once/day for a continuous 2 days, and the first injection was at 30 min prior to CP treatment; after 72 h post-injection of CP solution
Vehicle
0.5% DMSO in 0.9% NaCl injection
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Liquiritigenin 15 mg/kg body weight/daymodel groupliquiritigenin significantly reduced serum creatinine and urea nitrogen levels compared to the model group[3]
Liquiritigenin 15 mg/kg body weight/day
Model: Male BALB/c mice; CP-induced AKI mice model; n = 9 mice/group
Methods and source locations

Compound reported in the paper: Liquiritigenin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Liquiritigenin Protected against CP-Induced AKI in Mice (S3); 4. Materials and Methods > 4.2. Experimental Animals (S31, S34, S37, S39); Figure 1 legend (S91)

Serum creatinine levels: Serum creatinine levels; comparator: model group — 2. Results > 2.1. Liquiritigenin Protected against CP-Induced AKI in Mice (S3); Figure 1 legend (S91)

Liquiritigenin 15 mg/kg body weight/day · 2. Results > 2.1. Liquiritigenin Protected against CP-Induced AKI in Mice (S3); 4. Materials and Methods > 4.2. Experimental Animals (S34, S37, S39)

Alveolar Wall Thickening and Extracellular Matrix Deposition

Animal study · Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice [2]

Female mice with bleomycin-induced pulmonary fibrosis received oral Liquiritigenin at 25 mg/kg, 50 mg/kg, or 100 mg/kg. Compared with the pulmonary fibrosis model group, Liquiritigenin significantly reduced alveolar wall thickening and extracellular matrix deposition, with the most pronounced effect at 100 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lung morphology and ECM deposition were evaluated through HE and Masson staining.Reported result liquiritigenin significantly reduced the thickening of alveolar walls and deposition of extracellular matrix, with the most pronounced effect observed at the dose of 100 mg/kg[2]

Conditions shared by the study groups

Route
oral
Treatment course
on days 15–28; On day 29, the mice were euthanized for lung tissue collection.
Vehicle
0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kgpulmonary fibrosis model group (intratracheal bleomycin on day 0 + oral 0.9% saline on days 15–28)liquiritigenin significantly reduced the thickening of alveolar walls and deposition of extracellular matrix, with the most pronounced effect observed at the dose of 100 mg/kg[2]
Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg
Model: Female C57BL/6 mice (6–8 weeks old); bleomycin-induced pulmonary fibrosis mice
Methods and source locations

Compound reported in the paper: Liquiritigenin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Experimental animals (S1, S3, S4, S5, S9); Materials and methods > Histological analysis (S11); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S80, S81); Fig. 1 legend (S129)

Lung morphology and ECM deposition were evaluated through HE and Masson staining.: Lung morphology and ECM deposition were evaluated through HE and Masson staining.; comparator: pulmonary fibrosis model group (intratracheal bleomycin on day 0 + oral 0.9% saline on days 15–28) — Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S80); Fig. 1 legend (S129)

Liquiritigenin 25 mg/kg; 50 mg/kg; 100 mg/kg · Materials and methods > Experimental animals (S5, S9); Results > Liquiritigenin attenuates bleomycin-induced pulmonary fibrosis in mice (S80)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 578-86-9
Formula C15H12O4
Molecular Weight 256.25
SMILES
C1[C@H](OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 43 mg/mL (167.8 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Liquiritigenin Research References

  1. [1] Lee EJ, Shaikh S, Ahmad K, et al. Isolation and Characterization of Compounds from Glycyrrhiza uralensis as Therapeutic Agents for the Muscle Disorders. Int J Mol Sci (2021). PMID: 33467209 DOI: 10.3390/ijms22020876 Source material
  2. [2] Hua Q, Ren L. The SIRT1/Nrf2 signaling pathway mediates the anti-pulmonary fibrosis effect of liquiritigenin. Chin Med (2024). PMID: 38238857 DOI: 10.1186/s13020-024-00886-1 Source material
  3. [3] Zhou M, Dai Y, Ma Y, et al. Protective Effects of Liquiritigenin against Cisplatin-Induced Nephrotoxicity via NRF2/SIRT3-Mediated Improvement of Mitochondrial Function. Molecules (2022). PMID: 35744945 DOI: 10.3390/molecules27123823 Source material

Added to your cart

View Cart Checkout
Loading...